Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2015-005046-55-SE
EUCTR2015-005046-55-SE
Active, not recruiting
Phase 1

Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validation

meå University Hospital0 sitesJune 9, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
meå University Hospital
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 9, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
meå University Hospital

Eligibility Criteria

Inclusion Criteria

  • •\-Histologically confirmed intermediate/high risk prostate cancer
  • •\- \=2 months since last biopsy of the prostate
  • •\- Gleason 3\+4 or higher
  • •\-Written informed consent
  • •\-\> 18 years
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 15
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •\-Non MR\-safe implants or other contraindication to MRI,PET or CT
  • •\-WHO PS\>1
  • •\-TUR\-P within 6 months
  • •\-Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the pelvis
  • •\-Creatinine clearance \< 30ml/min (acc. to http://www.fass.se/LIF/produktfakta\-/kreatinin.jsp)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy.
EUCTR2015-004425-13-SESkåne University Hospital, Department of Oncology100
Active, not recruiting
Phase 1
Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open studyrenal cell cancer (RCC)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-003760-47-FRAssistance Publique Hôpitaux de Marseille44
Recruiting
Not Applicable
68Gallium-Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma (PIRC) – a pilot study
ACTRN12621000651886Olivia Newton-John Cancer Research Institute20
Completed
Not Applicable
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive TumorsProstate-specific Membrane Antigen Positive TumorsProstate CancerBreast CancerLung Cancer
NCT02978586Case Comprehensive Cancer Center8
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2016-000842-79-BEInstitut Jules Bordet75